Macrolides for acute lung injury

Chest

Volumn 141, Issue 5, 2012, Pages 1131-1132

  Noto, Michael J ^a   Wheeler, Arthur P ^a  

^a VANDERBILT UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZITHROMYCIN; BETA LACTAM ANTIBIOTIC; CLARITHROMYCIN; LISOFYLLINE; MACROLIDE; PLACEBO; QUINOLINE DERIVED ANTIINFECTIVE AGENT; REACTIVE OXYGEN METABOLITE; TETRACYCLINE DERIVATIVE;

ACUTE LUNG INJURY; ADULT RESPIRATORY DISTRESS SYNDROME; ANTIBACTERIAL ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ARTIFICIAL VENTILATION; ASTHMA; BRONCHIOLITIS; BRONCHIOLITIS OBLITERANS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CYSTIC FIBROSIS; CYTOKINE PRODUCTION; DOWN REGULATION; DRUG EFFECT; DRUG MECHANISM; EDITORIAL; HUMAN; IMMUNOMODULATION; LEUKOCYTE ACTIVATION; LEUKOCYTE MIGRATION INHIBITION; MORTALITY; NONHUMAN; OUTCOME ASSESSMENT; PHAGOCYTOSIS; PNEUMONIA; PRIORITY JOURNAL; PROTEIN SYNTHESIS INHIBITION; STREPTOCOCCUS PNEUMONIA; SURVIVAL RATE; TREATMENT DURATION; VENTILATOR ASSOCIATED PNEUMONIA;

EID: 84860574854     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1378/chest.11-3245     Document Type: Editorial

References (12)

1. Walkey AJ, Wiener RS. Macrolide antibiotics and survival in patients with acute lung injury. Chest. 2012;141(5):1153-1159.
2. The ARDS Clinical Trials Network; National Heart, Lung, and Blood Institute; National Institutes of Health. Randomized, placebo-controlled trial of lisofylline for early treatment of acute lung injury and acute respiratory distress syndrome. Crit Care Med. 2002;30(1):1-6.
3. Zarogoulidis P, Papanas N, Kioumis I, Chatzaki E, Maltezos E, Zarogoulidis K. Macrolides: from in vitro anti-inflammatory and immunomodulatory properties to clinical practice in respiratory diseases [published online ahead of print November 21, 2011]. Eur J Clin Pharmacol. doi:10.1007/s00228-011-1161- x.
4. Martínez JA, Horcajada JP, Almela M, et al. Addition of a macrolide to a beta-lactam-based empirical antibiotic regimen is associated with lower in-hospital mortality for patients with bacteremic pneumococcal pneumonia. Clin Infect Dis.2003;36(4):389-395. (Pubitemid 36241302)
5. Metersky ML, Ma A, Houck PM, Bratzler DW. Antibiotics for bacteremic pneumonia: improved outcomes with macrolides but not fluoroquinolones. Chest. 2007;131(2) : 466-473. (Pubitemid 46280407)
6. Giamarellos-Bourboulis EJ, Pechère JC, Routsi C, et al. Effect of clarithromycin in patients with sepsis and ventilator-associated pneumonia. Clin Infect Dis. 2008;46(8):1157-1164. (Pubitemid 351589897)
7. Saiman L, Marshall BC, Mayer-Hamblett N, et al. Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA. 2003;290(13):1749-1756. (Pubitemid 37430625)
8. Albert RK, Connett J, Bailey WC, et alCOPD Clinical Research Network. Azithromycin for prevention of exacerbations of COPD. N Engl J Med. 2011;365(8):689-698.
9. Akira M, Higashihara T, Sakatani M, Hara H. Diffuse panbronchiolitis: follow-up CT examination. Radiology. 189(2) : 559-562.
10. Friedlander AL, Albert RK. Chronic macrolide therapy in inflammatory airways diseases. Chest. 2010;138(5):1202-1212.
11. Wheeler AP, Bernard GR. Acute lung injury and the acute respiratory distress syndrome: a clinical review. Lancet. 2007; 369(9572):1553-1564. (Pubitemid 46670280)
12. Tamaoki J, Tagaya E, Yamawaki I, Sakai N, Nagai A, Konno K. Effect of erythromycin on endotoxin-induced microvascular leakage in the rat trachea and lungs. Am J Respir Crit Care Med. 1995;151(5):1582-1588.